Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
GAITHERSBURG, Md., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq: NVAX) today announced the appointment of Rachel King, Co-Founder and Chief Executive Officer of GlycoMimetics, Inc., to...
-
GAITHERSBURG, Md., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that its representatives will share data from its RSV F vaccine program via oral and poster...
-
GAITHERSBURG, Md., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that it will present at the Ladenburg Thalmann 2018 Healthcare Conference and the Cantor Global...
-
First participants enrolled in Phase 2 clinical trial of quadrivalent NanoFlu formulationsTop-line immunogenicity and safety data expected in the first quarter of 2019Phase 2 results will support...
-
GAITHERSBURG, Md., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that Novavax will participate in the B. Riley FBR Annual Healthcare Conference and the Citi 13th...
-
Novavax Delivers on Key Milestones Supporting its 2018 Objectives Company to Host Conference Call Today at 4:30 pm ET GAITHERSBURG, Md., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:...
-
GAITHERSBURG, Md., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced it will report its second quarter 2018 financial and operating results following the close of U.S....
-
NanoFluTM Phase 1/2 trial data published in a peer-reviewed letter to the editor in The New England Journal of MedicineNanoFlu demonstrates significantly improved immune responses against a panel of...
-
GAITHERSBURG, Md., May 09, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced its financial results for the first quarter ended March 31, 2018. First Quarter and Subsequent...
-
Prepare trial is assessing the efficacy of Novavax’ RSV F Vaccine for infants via maternal immunizationEnrollment of ~4,600 participants enables initiation of interim efficacy analysisTopline efficacy...